Lithium augmentation of antidepressants in treatment-refractory depression.

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 02/1998; 59 Suppl 6:28-33; discussion 34.
Source: PubMed

ABSTRACT The use of lithium to convert antidepressant nonresponders to responders is reviewed. Although there is little doubt that lithium is effective in a sizable percentage of patients who do not respond to tricyclic antidepressants (TCAs) and serotonin selective reuptake inhibitors (SSRIs), much remains obscure about this effect. Does it work preferentially on antidepressants that act primarily on serotonergic neurons, or is it equally effective with agents that act upon other neurotransmitter systems? When should lithium, compared with other strategies, be utilized in antidepressant nonresponders? Are certain subtypes of depression more likely than others to respond to lithium augmentation? The available literature highlights the efficacy of lithium as an augmenting agent in refractory depression and serves as an impetus for additional neurobiological and clinical studies of this phenomenon.


Available from: Charles B Nemeroff, Jun 11, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lithium has been used to augment the efficacy of antidepressant medications for more than 20 years. The present study examines whether evidence exists to support the clinical efficacy of lithium augmentation in refractory, treatment resistant depression. Studies were identified by searching Medline (1980 to August 2002) and by scanning the references of published reviews and standard textbooks. Studies were selected if they were open-labeled or double-blind, placebo-controlled or comparator trials that involved patients who had not responded to conventional antidepressants. 27 prospective studies were identified that included a total of 803 depressed patients displaying the following designs: 10 double-blind, placebo-controlled trials, 2 randomized, double-blind comparator trials, 2 randomized, open comparator trials, and 13 open-label trials. The majority of randomized controlled trials has demonstrated substantial efficacy of lithium augmentation in partial and non responders to antidepressant treatment. In the placebo-controlled trials, the response rate in the lithium group was 45% and in the placebo group 18% (p<0.001). Summarizing all open and controlled studies, approximately 50% of patients responded to lithium augmentation within 4 weeks. In conclusion, lithium is the foremost and most well-documented augmentation strategy in refractory depression.Therefore, it should be considered a first-line treatment strategy in patients with major depression who do not adequately respond to standard antidepressants.
    European Archives of Psychiatry and Clinical Neuroscience 06/2003; 253(3):132-9. DOI:10.1007/s00406-003-0430-9 · 3.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The therapeutic properties of lithium ions (Li+) are well known; however, the mechanism of their action remains unclear. To investigate this problem, we have isolated Li+-resistant mutants from Dictyostelium. Here, we describe the analysis of one of these mutants. This mutant lacks the Dictyostelium prolyl oligopeptidase gene (dpoA). We have examined the relationship between dpoA and the two major biological targets of lithium: glycogen synthase kinase 3 (GSK-3) and signal transduction via inositol (1,4,5) trisphosphate (IP3). We find no evidence for an interaction with GSK-3, but instead find that loss of dpoA causes an increased concentration of IP3. The same increase in IP3 is induced in wild-type cells by a prolyl oligopeptidase (POase) inhibitor. IP3 concentrations increase via an unconventional mechanism that involves enhanced dephosphorylation of inositol (1,3,4,5,6) pentakisphosphate. Loss of DpoA activity therefore counteracts the reduction in IP3 concentration caused by Li+ treatment. Abnormal POase activity is associated with both unipolar and bipolar depression; however, the function of POase in these conditions is unclear. Our results offer a novel mechanism that links POase activity to IP3 signalling and provides further clues for the action of Li+ in the treatment of depression.
    The EMBO Journal 06/1999; 18(10):2734-45. DOI:10.1093/emboj/18.10.2734 · 10.75 Impact Factor
  • Source
    Journal of Clinical Psychopharmacology 05/2001; 21(2):242-3. DOI:10.1097/00004714-200104000-00021 · 3.76 Impact Factor